Hospital Inpatient Pipeline Therapies 2025

This report offers hospital pharmacy leaders visibility into potential FDA approvals for budget planning purposes for the current fiscal year. With increasing numbers of FDA approvals of high-cost complex therapies, including gene therapies and other therapies that may require inpatient hospitalization for administration and/or monitoring, a focus on hospital inpatient pipeline therapies helps tailor health-system budgets and formulary management strategies. Such planning involves assessment of the potential adoption of these new therapies, if approved, and resulting increases in the costs of care.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.